Rhumbline Advisers Logic Bio Therapeutics, Inc. Transaction History

Rhumbline Advisers

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 05, 2021	SELL	$4.03 - $7.57 $53,760 - $100,983	-13,340 Closed	0 $0
Q1 2021 May 06, 2021	BUY	$6.8 - $9.16 $1,190 - $1,603	175 Added 1.33%	13,340 $97,000
Q4 2020 Feb 10, 2021	BUY	$5.29 - $9.1 $9,098 - $15,652	1,720 Added 15.03%	13,165 $100,000
Q3 2020 Nov 12, 2020	SELL	$5.41 - $9.45 $11,225 - $19,608	-2,075 Reduced 15.35%	11,445 $104,000
Q2 2020 Aug 13, 2020	BUY	$4.25 - $8.46 $14,110 - $28,087	3,320 Added 32.55%	13,520 $114,000
Q4 2019 Feb 05, 2020	BUY	$7.01 - $11.01 $1,402 - $2,202	200 Added 2.0%	10,200 $73,000
Q3 2019 Oct 23, 2019	SELL	$6.97 - $13.46 $522 - $1,009	-75 Reduced 0.74%	10,000 $108,000
Q2 2019 Aug 14, 2019	BUY	$9.77 - $17.08 $98,432 - $172,080	10,075 New	10,075 $131,000

Ticker LOGC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,962,700
Description
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.